IDEAYA Biosciences stock gains attention as IDE-849 moves toward Phase 3

IDEAYA Biosciences stock (ISIN US45166A1025) is in the spotlight as of September 17, 2026 after the company secured U.S. FDA alignment on a planned Phase 3 study for its DLL3-targeted antibody-drug conjugate IDE-849 in small-cell lung cancer, a move that could materially expand its late-stage pipeline according to BioWorld.

IDE-849 Phase 3 alignment lifts late-stage outlook

As BioWorld reported on September 17, 2026, IDE-849, IDEAYA’s DLL3-targeted antibody-drug conjugate, received alignment from the U.S. FDA on the design of a Phase 3 study in small-cell lung cancer, setting up a head-to-head race with Zai Lab’s competing DLL3 ADC candidate.

The article notes that IDE-849 progressed to this point roughly one year after IDEAYA reported positive Phase 1 data in small-cell lung cancer, underscoring a relatively rapid transition from early-stage to late-stage development compared with typical oncology timelines according to BioWorld Asia.

Valuation signals and recent share performance

On the valuation side, analysis from Simply Wall St on September 17, 2026 highlights that IDEAYA Biosciences shares had delivered a 20.81 percent return over the prior 90 days and an 11.46 percent gain year to date at a last close of USD 37.73.

The same analysis states that at USD 37.73, IDEAYA Biosciences stock trades on a price-to-sales multiple of 15.5 times, which screens as expensive on a straightforward revenue basis yet is described as trading 63.3 percent below an estimated intrinsic value based on future cash flows of USD 102.82 per share according to Simply Wall St.

For investors, that quantified gap between the current share price of USD 37.73 and the implied fair value of USD 102.82 frames IDEAYA Biosciences stock as potentially undervalued on a long-term cash flow basis, even though the elevated price-to-sales ratio points to high expectations embedded in the market’s view of its pipeline according to Simply Wall St.

Balance sheet, business model and sector context

The same Simply Wall St overview describes IDEAYA Biosciences as a precision medicine oncology company that develops targeted therapeutics for patient populations selected by molecular diagnostics in the United States, and characterizes its balance sheet as flawless while calling the stock slightly overvalued on some metrics according to Simply Wall St.

Sector studies underline that melanoma and other oncology indications remain highly competitive but also offer substantial room for innovation, with IDEAYA Biosciences listed among leading companies operating in melanoma clinical trials according to a pipeline review from OpenPR dated September 17, 2026.

Stock price level and investor takeaway

At its recent closing level of USD 37.73 on Nasdaq on a trading day shortly before September 17, 2026, IDEAYA Biosciences stock stands well below the USD 102.82 fair value estimate cited by Simply Wall St, with the 20.81 percent 90-day return indicating that the shares have already priced in some of the optimism around the IDE-849 Phase 3 path while still leaving a substantial valuation gap relative to that long-term cash flow model according to Simply Wall St.

More news and analyses on IDEAYA Biosciences stock